A Phase II and Biomarker Study of Cabozantinib in Patients with Advanced Cholangiocarcinoma
Excerpt:
Previously treated patients with unresectable or metastatic cholangiocarcinoma received cabozantinib...Of the baseline biomarkers, low plasma TIMP-1 was associated with longer PFS (p=0.029), and low IL-6 (p=0.021) and high sMET (p=0.0027) were correlated with longer OS.